|

AK112 Clinical Trials

16 actively recruiting trials

Also known as: Carboplatin/Cisplatin, Ivonescimab, Pemetrexed

Pipeline

Phase 2: 7Phase 3: 3Phase 1/2: 6

Top Sponsors

  • Akeso11
  • Tianjin Medical University Cancer Institute and Hospital1
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1
  • Tang-Du Hospital1
  • Sichuan University1

Indications

  • Cancer16
  • Lung Cancer3
  • Liver Disease2
  • Pancreatic Cancer2
  • Liver Cancer2

Other16 trials

A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Phase 2
A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
Phase 2
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Phase 1/2
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Phase 3
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase 1/2
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
Phase 2
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Phase 1/2
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Phase 2
A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
Phase 2
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Phase 1/2
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Phase 3
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Phase 3
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Phase 2
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
Phase 1/2
Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
Phase 2
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.